Skip to search formSkip to main contentSkip to account menu

Zirconium Zr 89 DFO-MSTP2109A

Known as: 89Zr-DFO-MSTP2109A 
A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody
The CD30-specific antibody–drug conjugate, brentuximab vedotin, is approved for the treatment of relapsed, refractory Hodgkin… 
2014
2014
Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: STEAP1 (Six Transmembrane Epithelial Antigen… 
2013
2013
Desferrioxamine-B promoted dissolution of an Oxisol and the effect of low-molecular-weight organic acids
This study was conducted to quantify the adsorption of desferrioxamine-B (DFO-B), a commercial trihydroxamate siderophore, onto… 
Highly Cited
2003
Highly Cited
2003
Steady-state dissolution kinetics of goethite in the presence of desferrioxamine B and oxalate ligands: implications for the microbial acquisition of iron
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)